Xinkuang Liu
Overview
Explore the profile of Xinkuang Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang Y, Liu X, Li A, Tang X
PLoS One
. 2022 Mar;
17(3):e0265655.
PMID: 35303016
Adenomatous polyposis coli (APC) is the most commonly mutated gene in colon cancer and can cause familial adenomatous polyposis (FAP). Hypermethylation of the APC promoter can also promote the development...
2.
Xu R, Liu X, Li A, Song L, Liang J, Gao J, et al.
J Mol Med (Berl)
. 2022 Feb;
100(4):585-598.
PMID: 35122106
Sorafenib acquired drug resistance during the treatment of hepatocellular carcinoma (HCC) reduces the efficacy of the drug. The immune escape effect induced by PD-L1 is largely associated with drug resistance...
3.
Song L, Xie C, Liu X, Huo Z, Xie Y, Gao J, et al.
J Biomed Nanotechnol
. 2021 Sep;
17(8):1690-1698.
PMID: 34544545
The metabolic product of type I collagen synthesis, intact procollagen type I N propeptide (intact PINP), is a potential marker of bone formation and osteoporosis, which is not affected by...
4.
Li A, Cao W, Liu X, Zhang Y, Ma Y, Xu R, et al.
J Cancer Res Clin Oncol
. 2020 Apr;
146(7):1737-1749.
PMID: 32342201
Purpose: The usual first-line strategy of wild-type EGFR (wtEGFR) non-small cell lung cancer (NSCLC) remains cisplatin-based chemotherapy. However, cisplatin often loses effectiveness because most tumors acquire drug resistance over time....
5.
Zhou S, Wei J, Wang Y, Liu X
Exp Ther Med
. 2020 Apr;
19(4):2733-2740.
PMID: 32226487
Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated mortality worldwide. Despite clinical advances, the survival rate of patients with HCC remains low, as most patients are diagnosed with HCC...
6.
Liu X, Xie C, Li A, Zhang Y, Liu X, Zhou S, et al.
Am J Transl Res
. 2020 Jan;
11(12):7255-7271.
PMID: 31934276
Desensitization of hepatocellular carcinoma (HCC) to paclitaxel chemotherapy is a major deterrent to successful treatment of the cancer. Abnormal activation of the PI3K/Akt/mTOR, pathway is a common outcome of chemotherapy...
7.
Li A, Zhang R, Zhang Y, Liu X, Wang R, Liu J, et al.
Am J Transl Res
. 2019 Oct;
11(9):5573-5585.
PMID: 31632530
Background: Sorafenib is an oral multi-kinase inhibitor that inhibits hepatocellular carcinoma (HCC) via the Ras/Raf/MAPK pathway. However, sorafenib loses effectiveness because most tumors acquire drug resistance over time. As the...
8.
Zhang Y, Xie C, Li A, Liu X, Xing Y, Shen J, et al.
Am J Transl Res
. 2019 Sep;
11(8):5134-5149.
PMID: 31497229
Oxaliplatin resistance limits its effectiveness in the treatment of hepatocellular carcinoma (HCC). Abnormal activation of the PI3K/AKT/mTOR pathway has been associated with decreased survival of HCC patients, anti-apoptosis after chemotherapeutic...
9.
Gan H, Chen L, Sui X, Wu B, Zou S, Li A, et al.
Mater Sci Eng C Mater Biol Appl
. 2018 Jul;
91:395-403.
PMID: 30033270
Although sorafenib (SFB) showed improved efficacy and much reduced the side effects in clinical liver cancer therapy, its therapeutic efficacy was still greatly limited due to short half-life in vivo...
10.
Tang X, Chen L, Li A, Cai S, Zhang Y, Liu X, et al.
Drug Deliv
. 2018 Jun;
25(1):1484-1494.
PMID: 29916268
Sorafenib (SFB) has improved the treatment of hepatocellular carcinoma (HCC) and has fewer severe side effects than other agents used for that purpose. However, due to a lack of tumor-specific...